早期乳腺癌保乳术后部分乳腺放疗(英国IMPORT LOW研究):多中心、开放标签、随机对照、3期非劣效试验的10年结局
IMPORT LOW试验纳入2018例低危早期乳腺癌保乳术后患者,随机分入全乳放疗组、减量放疗组和部分乳腺放疗组。10年随访显示,减量放疗组和部分乳腺放疗组的同侧乳腺肿瘤复发(IBTR)累积发生率与全乳放疗组相似,绝对差异未达非劣效界值,且三组中重度不良反应发生率相近。作者认为部分乳腺和减量放疗与全乳放疗同样安全有效,重申部分乳腺调强放疗可作为该人群的标准治疗。
要点
- 10年IBTR累积发生率:全乳组2.8%、减量组1.9%、部分乳腺组3.0%,差异未达非劣效界值。
- 三组中重度不良反应发生率相似,乳腺萎缩发生率最高(全乳组9%、减量组9%、部分乳腺组7%)。
- 作者认为部分乳腺调强放疗可作为低危早期乳腺癌保乳术后的标准治疗。
核心结论
- 长期随访进一步表明,在低危早期乳腺癌患者中,部分乳腺放疗和减量放疗与全乳放疗同样安全有效。
- 作者重申,在该人群中采用调强放疗实施的部分乳腺放疗可作为标准治疗。
研究设计与样本
- IMPORT LOW为随机、开放标签、多中心、非劣效、3期试验,2007年5月3日至2010年10月5日从英国30个放疗中心招募2018例患者。
- 纳入标准为年龄50岁及以上、因单灶浸润性导管腺癌行保乳手术、pT1-2(肿瘤≤3 cm)、N0-1(腋窝阳性淋巴结0至3枚)、组织学分级1-3级、显微镜下非癌组织切缘≥2 mm。
- 排除既往任何恶性肿瘤(非黑色素瘤皮肤癌除外)、已行乳房切除术、接受过新辅助或同期辅助化疗者。
- 患者按1:1:1随机分入全乳放疗组(40 Gy/15次)、减量放疗组(全乳36 Gy/15次+部分乳腺40 Gy/15次)或部分乳腺放疗组(40 Gy/15次),按治疗中心分层,未设盲。
- 主要终点为IBTR,10年结局在意向治疗人群中分析; clinician报告的晚期不良反应在所有有可用数据的参与者中按分配治疗分析。
主要发现
- 全乳放疗组675例、减量放疗组674例、部分乳腺放疗组669例;2例随后撤回知情同意。
- 中位年龄63岁(IQR 58-68);2016例中组织学分级1级854例(42%)、2级959例(48%)、3级200例(10%),3例肿瘤无法分级;淋巴结阳性59例(3%)。
- 中位随访:全乳放疗组120个月(IQR 119-122)、减量放疗组121个月(IQR 120-122)、部分乳腺放疗组120个月(IQR 119-122)。
- 10年内共报告45例IBTR事件:全乳放疗组674例中17例、减量放疗组673例中11例、部分乳腺放疗组669例中17例;累积发生率分别为2.8%(95%CI 1.8-4.5)、1.9%(95%CI 1.1-3.5)、3.0%(95%CI 1.9-4.8)。
- 与全乳放疗组相比,10年IBTR发生率的估计绝对差异:减量放疗组-1.02%(95%CI -1.98至0.99),部分乳腺放疗组0.16%(95%CI -1.28至2.89)。
临床怎么用
- 作者认为,在低危早期乳腺癌保乳术后患者中,部分乳腺调强放疗可作为标准治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The IMPORT LOW trial evaluated partial-breast radiotherapy with intensity-modulated radiotherapy in women with early-stage breast cancer at below average risk of ipsilateral breast tumour recurrence (IBTR). 5-year results concluded non-inferiority of IBTR for reduced-dose and partial-breast radiotherapy, with similar or lower frequency of adverse effects compared with whole-breast radiotherapy. We report outcomes after 10 years. METHODS: IMPORT LOW was a randomised, open-label, multicentre, non-inferiority, phase 3 trial. Women were eligible if they were aged 50 years or older and had had breast conservation surgery for unifocal invasive ductal adenocarcinoma, pT1-2 (tumour size of ≤3 cm), N0-1 (none to three positive axillary nodes), grades 1-3, with microscopic margins of non-cancerous tissue of 2 mm or more. Patients were ineligible if they had a previous malignancy of any kind (except non-melanomatous skin cancer), had undergone mastectomy, or had received neoadjuvant or concurrent adjuvant chemotherapy. Patients were randomly assigned (1:1:1) by randomly permuted blocks to radiotherapy regimens of 40 Gy in 15 fractions to the whole breast (whole-breast group), 36 Gy in 15 fractions to the whole breast plus 40 Gy in 15 fractions to the partial breast (reduced-dose group), or 40 Gy in 15 fractions to the partial breast (partial-breast group). Participants were stratified by treatment centre, without masking. The primary endpoint was IBTR. 10-year outcomes were analysed in the intention-to-treat population. Clinician-reported late adverse effects were evaluated in all participants with available data analysed according to allocated treatment. The study is registered in the ISRCTN registry (ISRCTN12852634) and is now complete. FINDINGS: 2018 patients were recruited between May 3, 2007, and Oct 5, 2010, from 30 radiotherapy centres in the UK and randomly assigned to the whole-breast group (n=675), reduced-dose group (n=674), or partial-breast group (n=669). Two participants subsequently withdrew consent. Median age was 63 years (IQR 58-68). 854 (42%) of 2016 patients had grade 1 tumours, 959 (48%) had grade 2 tumours, and 200 (10%) had grade 3 tumours (three tumours were ungradable); 59 (3%) had node-positive disease. Median follow-up was 120 months (IQR 119-122) for the whole-breast group, 121 months (IQR 120-122) for the reduced-dose group, and 120 months (IQR 119-122) for the partial-breast group. By 10 years, IBTR events were reported for 45 of 2016 participants: 17 of 674 in the whole-breast group, 11 of 673 in the reduced-dose group, and 17 of 669 in the partial-breast group, with cumulative incidence of 2·8% (95% CI 1·8-4·5), 1·9% (1·1-3·5), and 3·0% (1·9-4·8), respectively. The estimated absolute difference in 10-year IBTR incidence was -1·02% (95% CI -1·98 to 0·99) for the reduced-dose group and 0·16% (-1·28 to 2·89) for the partial-breast group compared with the whole-breast group. Similar low levels of moderate or marked adverse effects were recorded for participants in all three groups in 10-year clinical assessments. Breast shrinkage had the highest incidence (30 [9%] of 321 in the whole-breast group, 28 [9%] of 322 in the reduced-dose group, and 22 [7%] of 333 in the partial-breast group). INTERPRETATION: Long-term follow-up provides further evidence that partial-breast and reduced-dose radiotherapy are as safe and effective as whole-breast radiotherapy in patients with low-risk early breast cancer. These results reaffirm the use of partial-breast radiotherapy delivered with intensity-modulated radiotherapy in this population as standard of care. FUNDING: Cancer Research UK.
引用
- Kirby AM, Finneran L, Griffin CL, et al. Partial-breast radiotherapy after breast conservation surgery for women with early breast cancer (UK IMPORT LOW): 10-year outcomes from a multicentre, open-label, randomised, controlled, phase 3, non-inferiority trial. Lancet Oncol. 2025. PMID: 40516558. doi:10.1016/S1470-2045(25)00194-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。